Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. is a prominent player in the biopharmaceutical industry, focusing on the research, development, and production of vaccines for human use. The company has developed a diverse portfolio of vaccines, including the Recombinant Novel Coronavirus Vaccine, which stimulates immunity against COVID-19, and the Recombinant Mycobacterium Tuberculosis Fusion Protein (Ekear®), designed for the diagnosis of tuberculosis without interference from BCG vaccination. Their vaccine offerings also include various meningococcal polysaccharide vaccines and the Haemophilus Influenzae Type b Conjugate Vaccine, showcasing their commitment to addressing a wide range of infectious diseases.

Zhifei emphasizes a dual approach of research and marketing to enhance the commercialization of its products, supported by a robust R&D infrastructure that includes two dedicated research bases and a team of experts. The company has participated in significant national projects aimed at advancing medical technology and drug innovation. Additionally, Zhifei has established a comprehensive cold chain logistics system to ensure the safe storage and transportation of vaccines, further solidifying its role in public health initiatives. Through these efforts, Zhifei not only contributes to disease prevention but also actively engages in social responsibility, promoting health awareness and supporting community health initiatives.

China

Zhifei is a high-tech biological enterprise integrating the R&D, production, distribution as well as import & export to mainly produce vaccines for human use.

Infectious Diseases

25F No. 7, Jinyuan Road, Jiangbei District, CHONGQING, CQ | Chongqing 400020, CN

Anhui Zhifei Longcom Biopharmaceutical

Company Details